FDA Approves Addyi to Treat Low Desire in Women
Fewer Men with ED are Getting Penile Implants
History was made last week when the U.S. Food and Drug Administration approved Addyi (flibanserin), a drug designed to treat hypoactive sexual desire disorder (HSDD) in premenopausal women.
Sprout Pharmaceuticals, the maker of Addyi, expects to have it on the market by October 17.
Women with HSDD have no desire for or interest in sex, to the point that it causes them distress. Relationships may suffer, too.
Addyi is the first drug of its kind. But it's not for everyone. Click here more information about the drug, the approval process, and safety concerns.
Also, keep your eyes open for our next blog post, which will answer many of your questions about Addyi.
Developed in the 1960s, penile implants have long been a treatment option for men with erectile dysfunction (ED). But in recent years, the popularity of implants has started to wane.
In fact, the number of implant procedures dropped 50% among Medicare participants in the United States between 2001 and 2010.
Rates have also varied by U.S. region and by ethnicity. For example, penile implants appear to be more common in the southern and western parts of the U.S. and in African-American men.
Why are implant rates falling? Click here to find out. You'll also learn more about the study, the participants, and the demographics involved with implant procedures.